Digital Pathology: The scope and potential return on investment.
)
Digital Pathology: The scope and potential return on investment.
Dr David Snead
Professor Snead is a consultant pathologist at the University Hospitals Coventry and Warwickshire and Professor of Pathology Practice at the University of Warwick. He has been in post at Coventry for 20 years. He is the founding director of PathLAKE, one of the five Innovate UK funded centres of excellence for the development of artificial intelligence in digital pathology and radiology.
He is an international expert in the use of digital pathology having led Coventry to be one of the first hospitals in Europe to switch to digital pathology for routine diagnosis. His team published the worlds largest validation study on the use of digital pathology, and which was awarded the 2016 Roger Cotton Prize for best paper in Histopathology.
Prior to leading PathLAKE Prof Snead was for many years the clinical lead for cellular pathology at UHCW. This experience has given him a unique understanding of how innovative AI based solutions can be deployed to address the major challenges facing cellular pathology department across the NHS.
There are no shortcuts to achieving excellent results in AI solutions, but a career’s experience in diagnostic cellular pathology gives the understanding of where this kind of innovation can be best deployed for maximal gains in quality and efficiency.